0000950170-23-067790.txt : 20231204 0000950170-23-067790.hdr.sgml : 20231204 20231204163610 ACCESSION NUMBER: 0000950170-23-067790 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231129 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231204 DATE AS OF CHANGE: 20231204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 231463729 BUSINESS ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 BUSINESS PHONE: 7209402200 MAIL ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 8-K 1 abio-20231129.htm 8-K 8-K
false000090765400009076542023-11-292023-11-29

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 4, 2023 (November 29, 2023)

 

 

ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-22873

36-3855489

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10170 Church Ranch Way

Suite 100

 

Westminster, Colorado

 

80021

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (720) 940-2200

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common

 

ABIO

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Amendment to Retention Bonus Letter of Thomas A. Keuer and C. Jeffrey Dekker

On November 29, 2023, the compensation committee of the board of directors of ARCA biopharma, Inc., a Delaware corporation (“ARCA” or the "Company"), approved the amendment of certain retention bonus letters between ARCA and each of Thomas A. Keuer and C. Jeffrey Dekker to (i) increase the aggregate amount of the retention bonus with respect to each such executive by 50%, to $150,000, and (ii) in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards, provide that $35,000 of each such executive’s retention bonus will become payable on December 8, 2023, subject to each such executive’s continued employment in good standing and compliance with the ARCA’s policies and procedures through such date (each such portion of the applicable executive’s retention bonus, the “First Bonus Payment”). The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $115,000, will become payable consistent with the original terms of the applicable retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker, including the First Bonus Payment, will be paid by ARCA via payroll within 30 business days of the date of occurrence of the applicable “Payment Event Date” (as such term is otherwise defined in the applicable amendment to the retention bonus letter). Each such retention bonus letter will otherwise remain subject to its original terms and conditions.

The original retention bonus letters between ARCA and each of Thomas A. Keuer and C. Jeffrey Dekker are incorporated herein by reference to Exhibits 10.1 and 10.2, respectively, of the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 9, 2022.

The foregoing description of the amendment to the retention bonus letter of Thomas A. Keuer and the amendment to the retention bonus letter of C. Jeffrey Dekker is not complete and is qualified in its entirety by reference to the full text of each such amendment, copies of which are filed as Exhibits 10.1 and 10.2, respectively to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number

Description

10.1

Amendment to Retention Bonus Letter, dated December 4, 2023, by and among ARCA biopharma, Inc. and Thomas A. Keuer.

10.2

 

Amendment to Retention Bonus Letter, dated December 4, 2023, by and among ARCA biopharma, Inc. and C. Jeffrey Dekker.

104

Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARCA biopharma, Inc.
(Registrant)

 

 

 

 

Date:

December 4, 2023

By:

/s/ C. Jeffrey Dekker

 

 

 

Name: C. Jeffrey Dekker
Title: Chief Financial Officer

 

 EX-10.1 2 abio-ex10_1.htm EX-10.1 EX-10.1

Exhibit 10.1

ARCA BIOPHARMA, INC.

AMENDMENT TO RETENTION BONUS LETTER

This amendment (the “Amendment”) is entered into effective as of December 4, 2023 by and between Thomas A. Keuer (“Executive”) and ARCA biopharma, Inc. (the “Company,” and together with Executive, the “Parties”).

WHEREAS, the Parties entered into a retention bonus letter agreement dated December 8, 2022 (the “Retention Agreement”).

WHEREAS, the Parties desire to amend the Retention Agreement to increase the aggregate amount of the cash retention bonus by 50%, and to provide that a portion of the cash retention bonus will become payable to Executive on December 8, 2023, and the remainder of the cash retention bonus will become payable to Executive upon the original payment event date set forth in the Retention Agreement, subject to the Executive remaining actively and continuously employed and in good standing with the Company through the applicable payment event date.

NOW, THEREFORE, in considerations of the promises, mutual covenants, and above recitals, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, Executive and the Company hereby agree as follows:

1.
The first full paragraph at the top of the first page of the Retention Agreement is hereby amended and restated in its entirety as follows:

“In recognition of your continued service with ARCA biopharma, Inc. (the “Company”), we are pleased to offer you the opportunity to receive a cash retention bonus in the aggregate amount of $150,000, less applicable withholdings and deductions required by law (the “Retention Bonus”). Subject to the terms of this letter, you will become eligible to receive a portion of the Retention Bonus in the amount of $35,000 on December 8, 2023 (the date of occurrence of such event, the “Payment Event One Date”), and the remaining portion of the Retention Bonus in the amount of $115,000 upon the earlier to occur of the following: (i) a Corporate Transaction (as defined below), or (ii) the date that the board of directors of the Company (the “Board”) approves certain clinical development decisions (the date of occurrence of such event, the “Payment Event Two Date,” and together with Payment Event One Date, each a “Payment Event Date”). Any payment related to the Retention Bonus will be processed and paid to you by the Company via payroll within thirty (30) business days of the date of occurrence of the applicable Payment Event Date, subject to the terms of this letter.”

 

2.
The second full paragraph from the top of the first page of the Retention Agreement is hereby amended and restated in its entirety as follows:

“In order to receive each portion of the Retention Bonus, you must (i) remain actively and continuously employed in good standing by the Company through the applicable Payment Event Date, and (ii) otherwise comply with the terms and conditions of this letter and the Company’s policies and procedures. In

1

 

 

order to be considered in “good standing,” you must have been employed continuously from the date hereof to the applicable Payment Event Date and you must not be the subject of any disciplinary warning, whether written or oral and must not have behaved in a manner that would be grounds for discharge for “Cause” (as defined below).”

 

3.
The last sentence of the third full paragraph from the top of the first page of the Retention Agreement is hereby amended and restated in its entirety as follows:

“For clarity, should your employment terminate for any reason prior to a Payment Event Date, you will not have earned, and therefore will not receive, the portion of the Retention Bonus related to such Payment Event Date.”

4.
Full Force and Effect. To the extent not expressly amended hereby, the Agreement and Amendment shall remain in full force and effect.
5.
Entire Agreement. This Amendment, the Amendment and the Agreement constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof, respectively. This Amendment may be amended at any time only by mutual written agreement of the Parties.
6.
Counterparts. This Amendment may be executed in counterparts, all of which together shall constitute one instrument, and each of which may be executed by less than all of the parties to this Amendment.
7.
Governing Law. This Amendment will be governed by the laws of the State of Colorado (with the exception of its conflict of laws provisions).

 

-2-

 

IN WITNESS WHEREOF, each of the Parties has executed this Amendment, in the case of the Company by its duly authorized officer, effective as of the date set forth above.

 

ARCA BIOPHARMA, INC.

 

EXECUTIVE

 

 

 

 

 

/s/ Michael Bristow

 

/s/ Thomas A. Keuer

By:

Dr. Michael Bristow

By:

Thomas A. Keuer

Date:

12/4/23

Date:

12/4/23

 

-3-

 EX-10.2 3 abio-ex10_2.htm EX-10.2 EX-10.2

Exhibit 10.2

ARCA BIOPHARMA, INC.

AMENDMENT TO RETENTION BONUS LETTER

This amendment (the “Amendment”) is entered into effective as of December 4, 2023 by and between C. Jeffrey Dekker (“Executive”) and ARCA biopharma, Inc. (the “Company,” and together with Executive, the “Parties”).

WHEREAS, the Parties entered into a retention bonus letter agreement dated December 8, 2022 (the “Retention Agreement”).

WHEREAS, the Parties desire to amend the Retention Agreement to increase the aggregate amount of the cash retention bonus by 50%, and to provide that a portion of the cash retention bonus will become payable to Executive on December 8, 2023, and the remainder of the cash retention bonus will become payable to Executive upon the original payment event date set forth in the Retention Agreement, subject to the Executive remaining actively and continuously employed and in good standing with the Company through the applicable payment event date.

NOW, THEREFORE, in considerations of the promises, mutual covenants, and above recitals, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, Executive and the Company hereby agree as follows:

1.
The first full paragraph at the top of the first page of the Retention Agreement is hereby amended and restated in its entirety as follows:

“In recognition of your continued service with ARCA biopharma, Inc. (the “Company”), we are pleased to offer you the opportunity to receive a cash retention bonus in the aggregate amount of $150,000, less applicable withholdings and deductions required by law (the “Retention Bonus”). Subject to the terms of this letter, you will become eligible to receive a portion of the Retention Bonus in the amount of $35,000 on December 8, 2023 (the date of occurrence of such event, the “Payment Event One Date”), and the remaining portion of the Retention Bonus in the amount of $115,000 upon the earlier to occur of the following: (i) a Corporate Transaction (as defined below), or (ii) the date that the board of directors of the Company (the “Board”) approves certain clinical development decisions (the date of occurrence of such event, the “Payment Event Two Date,” and together with Payment Event One Date, each a “Payment Event Date”). Any payment related to the Retention Bonus will be processed and paid to you by the Company via payroll within thirty (30) business days of the date of occurrence of the applicable Payment Event Date, subject to the terms of this letter.”

 

2.
The second full paragraph from the top of the first page of the Retention Agreement is hereby amended and restated in its entirety as follows:

“In order to receive each portion of the Retention Bonus, you must (i) remain actively and continuously employed in good standing by the Company through the applicable Payment Event Date, and (ii) otherwise comply with the terms and conditions of this letter and the Company’s policies and procedures. In

1

 

 

order to be considered in “good standing,” you must have been employed continuously from the date hereof to the applicable Payment Event Date and you must not be the subject of any disciplinary warning, whether written or oral and must not have behaved in a manner that would be grounds for discharge for “Cause” (as defined below).”

 

3.
The last sentence of the third full paragraph from the top of the first page of the Retention Agreement is hereby amended and restated in its entirety as follows:

“For clarity, should your employment terminate for any reason prior to a Payment Event Date, you will not have earned, and therefore will not receive, the portion of the Retention Bonus related to such Payment Event Date.”

4.
Full Force and Effect. To the extent not expressly amended hereby, the Agreement and Amendment shall remain in full force and effect.
5.
Entire Agreement. This Amendment, the Amendment and the Agreement constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof, respectively. This Amendment may be amended at any time only by mutual written agreement of the Parties.
6.
Counterparts. This Amendment may be executed in counterparts, all of which together shall constitute one instrument, and each of which may be executed by less than all of the parties to this Amendment.
7.
Governing Law. This Amendment will be governed by the laws of the State of Colorado (with the exception of its conflict of laws provisions).

 

-2-

 

IN WITNESS WHEREOF, each of the Parties has executed this Amendment, in the case of the Company by its duly authorized officer, effective as of the date set forth above.

 

ARCA BIOPHARMA, INC.

 

EXECUTIVE

 

 

 

 

 

/s/ Michael Bristow

 

/s/ C. Jeffrey Dekker

By:

Dr. Michael Bristow

By:

C. Jeffrey Dekker

Date:

12/4/23

Date:

12/4/23

 

-3-

 EX-101.SCH 4 abio-20231129.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 abio-20231129_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 6 abio-20231129_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 29, 2023
Entity Registrant Name ARCA biopharma, Inc.
Entity Central Index Key 0000907654
Entity Emerging Growth Company false
Entity File Number 000-22873
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-3855489
Entity Address, Address Line One 10170 Church Ranch Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Westminster
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80021
City Area Code (720)
Local Phone Number 940-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol ABIO
Security Exchange Name NASDAQ
XML 8 abio-20231129_htm.xml IDEA: XBRL DOCUMENT 0000907654 2023-11-29 2023-11-29 false 0000907654 8-K 2023-11-29 ARCA biopharma, Inc. DE 000-22873 36-3855489 10170 Church Ranch Way Suite 100 Westminster CO 80021 (720) 940-2200 false false false false Common ABIO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " "$A(1799!YDAD! #/ P $P @ &T L$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #^$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports abio-20231129.htm abio-20231129.xsd abio-20231129_lab.xml abio-20231129_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "abio-20231129.htm": { "nsprefix": "abio", "nsuri": "http://www.arcabiopharma.com/20231129", "dts": { "inline": { "local": [ "abio-20231129.htm" ] }, "schema": { "local": [ "abio-20231129.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "abio-20231129_lab.xml" ] }, "presentationLink": { "local": [ "abio-20231129_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_6ba0ecbe-3ebd-4ae3-99d6-a91491d37965", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "abio-20231129.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6ba0ecbe-3ebd-4ae3-99d6-a91491d37965", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "abio-20231129.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.arcabiopharma.com/20231129/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000950170-23-067790-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-067790-xbrl.zip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end